The Impact of Cholangiocarcinoma on Patients

October 2020, Vol 1, No 2

At the 2020 virtual conference of the Cholangiocarcinoma Foundation (CCF), results of a patient survey conducted in summer 2019 by the CCF and Incyte Corporation, provided real-life responses from patients regarding the impact of a cholangiocarcinoma (CCA) diagnosis on patients with this rare disease.

The survey objectives were to understand the impact of CCA on the patient, including the effect of receiving the diagnosis; understand the experiences of patients with CCA in terms of the treatment decision; highlight the individual patient’s perspective on the therapies and outcomes; and explore the impact of disease management on the patient’s quality of life and psychosocial aspects.

Overall, the 3 key takeaways from the survey were:

  • It is a long journey from symptom manifestation to diagnosis
  • 33% of the patients were initially misdiagnosed
  • The diagnosis of CCA was especially challenging for patients with intrahepatic CCA.

Patient Survey

The results were presented by Kristen Bibeau, PhD, MSPH, Senior Director and Head, Global Health Outcomes and Real-World Evidence Generation, Incyte Corporation, Wilmington, DE.

A total of 707 patients with CCA were recruited for a 30-minute online survey. Of the 7070 patients, 157 patients noted their disease was stage I-II, and 364 patients noted it was stage IIIa, indicating that they could still have surgery as a treatment option. In addition, 97 patients stated that their disease was at stage IIIb, which means they were not eligible for surgery, and 43 patients had metastatic (stage IV) disease. Furthermore, 30 patients indicated that their disease was in remission. The majority (77%) of the respondents were male, and 63% of the patients were older than age 45 years.

The respondents noted that on average, it took 22 months from the time they first noticed symptoms to the time they received a diagnosis of CCA. Not surprisingly, a significant proportion of the patients reported that the stage of their CCA progressed between the time they were first diagnosed and when they responded to the survey.

The survey also asked about the anatomic location of the patient’s tumor. Overall, 47% of the patients stated that they were diagnosed with a perihilar CCA, 41% had an intrahepatic CCA, and 12% were diagnosed with a distal extrahepatic tumor.

Misdiagnosis

When the patients were asked if they were misdiagnosed, more than one-third (35%) indicated that they were initially diagnosed with another type of cancer. Specifically, the following percentages of patients were initially misdiagnosed with the following tumors:

  • 52%—gallbladder cancer
  • 16%—hepatocellular cancer
  • 12%—pancreatic cancer
  • 12%—ampulla of Vater cancer
  • 9%—cancer of unknown origin
  • 3%—unknown site.

Of note, 52% of the patients indicated that they sought a second or third opinion before they were diagnosed with CCA, and that on average, they visited 2.5 oncologists before they received the correct diagnosis of CCA.

Treatment Decisions

Patients were asked to identify the key driver for the treatment selection for their tumor. Not surprisingly, 61% noted that their physician’s judgment was the main driver of the treatment selection. However, it was surprising that the second top response, 40% of the patients, for the driver of treatment decision was the impact of a treatment choice on their quality of life.

This showed that quality of life was the most important aspect of treatment selection even for patients with later-stage (stages IIIb-IV) disease. For this group of patients, quality of life rivaled physician judgment as the most critical factor in selecting a treatment regimen (23% vs 26%).

CCA Symptoms

Patients with CCA have a wide variety of symptoms, such as fatigue, diarrhea, jaundice, abdominal pain, constipation, weight loss, pruritus, anxiety, depression, as well as other manifestations related to their disease.

The survey revealed that there was not one symptom that had a greater impact on a patient’s quality of life over another. Rather, patients rated most symptoms as having a similarly negative effect on their quality of life and on their day-to-day activities.

The one common characteristic related to disease symptoms observed in the survey was among patients with intrahepatic CCA and stage IIIa disease (ie, those eligible for surgical resection). This patient group reported the most symptoms and suffered from their symptoms more often than other patients.

Related Items

Importance of Proper Nutrition in Patients With Cholangiocarcinoma
June 2023, Vol 4, No 2
A specialist in oncology nutrition and the caregiver of a patient with cholangiocarcinoma discuss the importance of proper nutrition in achieving positive cancer outcomes.
Physician Debate: Is Chemotherapy Still the Backbone for CCA Treatment?
June 2023, Vol 4, No 2
Dr Rachna Shroff and Dr Madhulika Eluri debated whether it is time to move away from chemotherapy as a mainstay in the treatment of cholangiocarcinoma.
Incorporating ctDNA Into Clinical Trial Design
June 2023, Vol 4, No 2
Cholangiocarcinoma experts discussed potential applications of liquid biopsies using circulating tumor DNA.
Harnessing the Microbiome to Optimize Response to Immunotherapy
June 2023, Vol 4, No 2
Dr Marina Barcena-Varela described a study that aims to understand how the microbiome affects cholangiocarcinoma tumorigenesis based on genetic alterations and response to targeted and immunotherapy.
New Treatment Strategy for FGFR2 Fusion–Positive CCA
June 2023, Vol 4, No 2
Dr Michael E. Lidsky described a novel investigative murine model of FGFR2 fusion–positive intrahepatic cholangiocarcinoma and how it may enhance treatment outcomes.
CDX-1140 Plus Capecitabine, Oxaliplatin, and Pembrolizumab in Advanced BTC
June 2023, Vol 4, No 2
Dr Cecilia Monge presented the rationale and study design for a new phase 2 study investigating the CD40 agonist CDX-1140 in combination with capecitabine, oxaliplatin, and pembrolizumab in advanced biliary tract cancer.
Emerging Therapeutic Targets for CCA From Translational Research
June 2023, Vol 4, No 2
Dr Tim F. Greten discussed emerging targets for the treatment of cholangiocarcinoma coming from translational research studies.
Advances in CAR T-Cell Therapy in CCA
June 2023, Vol 4, No 2
Dr Mark O’Hara discussed the growing potential of CAR T-cell therapy in cholangiocarcinoma.
The Future of Clinical Trial Design in CCA Informed by Past Experiences
June 2023, Vol 4, No 2
Dr Sandra J. Casak discussed future thinking regarding clinical trials in cholangiocarcinoma, including a “seamless” oncology drug development paradigm.
Hot Topics on Cholangiocarcinoma at the 2023 Cholangiocarcinoma Foundation Annual Conference
By Melinda Bachini; Juan W. Valle, MB ChB, MSc, FRCP
Videos
On April 14, 2023, we presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 Cholangiocarcinoma Foundation Annual Conference.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: